Scott Ellis

Scott Ellis is a seasoned expert in the life sciences sector, currently serving as a Scientific Operating Partner at Oxford Science Enterprises since June 2024, where responsibilities include collaborating with the investment team and fostering growth within Life Science businesses associated with Oxford University. Prior to this role, Scott held the position of Executive Director at Novartis from February 2022 to April 2024, overseeing the Gyroscope Research team post-acquisition. Scott's earlier experience encompasses leadership roles in research and development at Gyroscope Therapeutics Ltd and Oxford BioMedica, focusing on gene and cell therapies. Academic contributions include postdoctoral positions at the Wellcome Trust Centre for Human Genetics and Brunel University London. Scott earned a Ph.D. in Retrovirology and Mouse Genetics from the National Institute for Medical Research after obtaining a BSc (Hons) in Applied Biology from the University of Bath.